Compare Organon & Co. Common Stock (OGN) vs Rent the Runway Inc (RENT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Rent the Runway Inc — how do they compare? Organon & Co. Common Stock trades at $13.73 (market cap $3.61B), while Rent the Runway Inc trades at $1.71 (market cap $57.68M). The key difference: Organon & Co. Common Stock is far larger — about 62.6× Rent the Runway Inc's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Rent the Runway Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Rent the Runway Inc for 56 Days on average.
| OGN | RENT | |
|---|---|---|
Market Cap | $3.61B | $57.68M |
Volume | 1,808,049 | 79,227 |
Sector | Health | Consumer Cyclical |
52-Week High | $13.81 | $9.39 |
52-Week Low | $5.70 | $1.55 |
Typical Hold Time | 0 Days | 56 Days |
Enterprise Value | $11.03B | $224.68M |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
RENT trades at $1.78, down 2.73% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported Q2 2026 revenue of $97.7 million, up 20.8% year-over-year, and named Paige Thomas as CEO. Despite negative shareholder equity and a high debt load, profitability is improving, with net income margin turning positive in 2026. Analyst sentiment is cautiously optimistic with a 42% buy rating.
The outlook is cautiously optimistic as revenue growth accelerates and cost controls improve margins, but significant risks remain from negative equity, high debt, and ongoing legal investigations. The stock presents a high-risk, high-reward opportunity contingent on successful execution of the turnaround plan under new leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Rent the Runway Inc
Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe, or buy designer apparel and accessories.
Read more on RENT →
